Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > BUSINESS
BUSINESS
- Merck Serono Initiates Voluntary Recall of Ovulation Inducer Serophene Due to Deviation from In-House Specifications
September 1, 2015
- GSK Paid 9.3 Billion Yen to Physicians, Medical Institutions in 2014
August 31, 2015
- Towa Raises Production Target to 14 Billion Tablets: Pres. Yoshida
August 31, 2015
- Hisamitsu Starts PII Study of Analgesic Transdermal Patch for Lower Back Pain in Japan
August 31, 2015
- Seikagaku to Cease Development of Rheumatoid Arthritis Treatment Licensed from Can-Fite
August 31, 2015
- Takeda Inks Deal with Nanotherapeutics to Expand Vaccine Technology Rights
August 28, 2015
- MTPC Chief Hints at No Major Merger, Plans Departure from Go-It-Alone Policy
August 28, 2015
- Jardiance Reduces Cardiovascular Risks: BI, Lilly
August 28, 2015
- Ono Files for Multiple Myeloma Treatment Carfilzomib in Japan
August 27, 2015
- Lixiana Recommended by UK’s NICE as Venous Thromboembolism Treatment Under National Health Service: Daiichi Sankyo
August 27, 2015
- Tresiba Approved for Pediatric Use: Novo Nordisk
August 27, 2015
- ASKA to Launch Authorized Generics of Takeda’s Unisia
August 26, 2015
- Artist Approved for Tachycardiac Atrial Fibrillation: Daiichi Sankyo
August 26, 2015
- Cravit Approved for Pulmonary Tuberculosis: Daiichi Sankyo
August 26, 2015
- Ono, Novartis Gain Approval of One-Step Titration Regimen for AD Drug Rivastigmine
August 26, 2015
- Chugai Files CellCept for Lupus Nephritis Based on Information in Public Domain
August 26, 2015
- Novo Nordisk to Roll Out NovoThirteen on Aug. 27
August 25, 2015
- Japan to Participate in Global PIII Study of Forxiga for Type 1 Diabetes: AZ
August 25, 2015
- ASCO Immunotherapy Roundup - 8: 5 Immune Checkpoint Inhibitors Projected to Rake in 2 Trillion Yen in 2020
August 25, 2015
- Eli Lilly Files for Psoriasis Treatment Ixekizumab in Japan
August 24, 2015
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…